Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 427

Emerging nanotechnology and molecular innovations present promising strategies in combating inflammation and diabetes, aiming to transform treatment methods and improve patient outcomes significantly.

The intersection of nanotechnology and biomedicine has sparked significant advances in the treatment and understanding of both inflammatory and metabolic diseases. These advances have brought about innovative solutions to longstanding medical challenges, such as rheumatoid arthritis (RA) and type 2 diabetes mellitus (T2DM), diseases that collectively affect millions worldwide.

Read more | >

Summary: A recent study showcases a significant leap in the study of brain oscillations, particularly ripples, which are crucial for memory organization and are affected in disorders like epilepsy and Alzheimer’s. Researchers have developed a toolbox of AI models trained on rodent EEG data to automate and enhance the detection of these oscillations, proving their efficacy on data from non-human primates.

This breakthrough, stemming from a collaborative hackathon, offers over a hundred optimized machine learning models, including support vector machines and convolutional neural networks, freely available to the scientific community. This development opens new avenues in neurotechnology applications, especially in diagnosing and understanding neurological disorders.

Read more | >

Every time a cell divides, its DNA is duplicated so that the two daughter cells have the same genetic material as their parent. This means that, millions of times a day, a biochemical wonder takes place in the body: the copying of the DNA molecule. It is a high-precision job carried out by specific proteins and includes systems to protect against potential errors that could lead to diseases such as cancer.

One of these anti-failure systems has just been discovered by researchers in the DNA Replication Group at the Spanish National Cancer Research Centre (CNIO), led by Juan Méndez. It is based on a protein that ensures that DNA is copied only once, as it should be, and not twice or more.

The work is published in The EMBO Journal.

Read more | >

Generative AI is getting plenty of attention for its ability to create text and images. But those media represent only a fraction of the data that proliferate in our society today. Data are generated every time a patient goes through a medical system, a storm impacts a flight, or a person interacts with a software application.

Using generative AI to create realistic around those scenarios can help organizations more effectively treat patients, reroute planes, or improve software platforms—especially in scenarios where real-world data are limited or sensitive.

For the last three years, the MIT spinout DataCebo has offered a generative software system called the Synthetic Data Vault to help organizations create synthetic data to do things like test software applications and train machine learning models.

Read more | >

Researchers led by Northwestern University and Washington University School of Medicine in St. Louis have developed a new, first-of-its-kind sticker that enables clinicians to monitor the health of patients’ organs and deep tissues with a simple ultrasound device.

When attached to an organ, the soft, tiny sticker changes in shape in response to the body’s changing pH levels, which can serve as an sign for post-surgery complications such as anastomotic leaks. Clinicians then can view these shape changes in real time through ultrasound imaging.

Currently, no existing methods can reliably and non-invasively detect anastomotic leaks—a life-threatening condition that occurs when gastrointestinal fluids escape the digestive system. By revealing the leakage of these fluids with high sensitivity and , the non-invasive sticker can enable earlier interventions than previously possible. Then, when the patient has fully recovered, the biocompatible, bioresorbable sticker simply dissolves away—bypassing the need for surgical extraction.

Read more | >

Scientists at the National Institutes of Health have discovered antibodies that attack a difficult-to-detect area of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was recently published in the journal Immunity.

Influenza, or flu, sickens millions of people across the globe each year and can lead to severe illness and death. While vaccination against influenza reduces the burden of the disease, updated vaccines are needed each season to provide protection against the many strains and subtypes of the rapidly evolving virus. Vaccines that provide protection against a broad range of influenza viruses could prevent outbreaks of new and reemerging flu viruses without the need for yearly vaccine reformulation or vaccinations.

Read more | >

A Michigan state senator introduced a bill that would require health insurance companies in the state to cover cutting-edge cancer treatments, even if they are not categorized as a “cancer drug.”

State Sen. Jeff Irwin (D-Mich.) announced his new bill in a video on X, formerly Twitter, on Tuesday. The legislation would build on an existing law that already says cancer drugs must be covered by health insurance companies.

Read more | >

Researchers at the University of Colorado Anschutz Medical Campus have found that inhibiting a key protein can stop the destruction of synapses and dendritic spines commonly seen in Alzheimer’s disease.

The study, whose first author is Tyler Martinez, a student in the Pharmacology and Molecular Medicine PhD program at the University of Colorado School of Medicine, was published recently in the journal eNeuro.

The researchers, using rodent neurons, found that targeting a protein called Mdm2 with an experimental cancer drug known as nutlin, stopped neurotoxic amyloid-b peptides that accumulate in Alzheimer’s disease (AD) from overly pruning synapses.

Read more | >